Skip to main content
OpenTrials
Completed

NCT Number: NCT07465900

Slowing Axial Elongation in Pediatric Myopia Using C.A.R.E. Technology

This prospective interventional study evaluates the effectiveness of Cylindrical Annular Refractive Element (C.A.R.E.) spectacle lenses in slowing axial elongation and myopia progression in children aged 6-12 years. A total of 100 participants with myopia ranging from -0.75 to -6.00 diopters were enrolled and prescribed C.A.R.E. spectacle lenses for full-time wear over a 12-month period. Clinical examinations are conducted at baseline, 6 months, and 12 months and include measurements of axial length, cycloplegic refraction, and visual acuity.

The primary outcome measure is the change in axial length over the 12-month study period. Secondary outcomes include changes in spherical equivalent refractive error, visual acuity, and safety outcomes related to spectacle lens wear.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

6 year–12 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Benha University

Banhā, Benha, 13111, Egypt

About this study

This prospective interventional clinical study was designed to evaluate the effectiveness of Cylindrical Annular Refractive Element (C.A.R.E.) spectacle lenses in slowing axial elongation in children with myopia over a one-year period. The study follows the principles of the Declaration of Helsinki and received approval from the Al-Azhar University Institutional Ethics Committee (Approval No. Ophth._12/2023). Written informed consent was obtained from the parents or legal guardians of all participants prior to enrollment.

Participants

A total of 100 children aged 6-12 years with spherical equivalent refractive error between -0.75 and -6.00 diopters and astigmatism ≤1.50 diopters were recruited. Eligible participants were required to have best-corrected visual acuity of 0.1 logMAR or better and no history of ocular pathology or previous ocular surgery.

Children with amblyopia, strabismus, keratoconus, previous myopia control treatment (such as atropine therapy or orthokeratology), or poor compliance with spectacle wear were excluded.

Intervention

All participants were prescribed spectacle lenses incorporating Cylindrical Annular Refractive Element (C.A.R.E.) technology. These lenses contain a central optical zone for distance correction surrounded by concentric annular cylindrical elements designed to modify peripheral retinal defocus. Participants were instructed to wear the spectacles full-time during waking hours throughout the study period.

Study Procedures

Participants undergo comprehensive ophthalmologic examinations at baseline, 6 months, and 12 months. Assessments include:

Uncorrected visual acuity (UCVA)

Best-corrected visual acuity (BCVA)

Cycloplegic refraction

Axial length measurement using non-contact optical biometry

Outcome Measures

The primary outcome measure is the change in axial length over the 12-month follow-up period. Secondary outcomes include changes in spherical equivalent refractive error, visual acuity, and safety outcomes associated with spectacle lens wear.

Statistical Analysis

Statistical analysis will be performed using SPSS software. Continuous variables will be expressed as mean ± standard deviation. Data distribution will be evaluated using the Shapiro-Wilk test. Changes in axial length and refractive error over time will be analyzed using repeated-measures analysis of variance (ANOVA) or paired statistical tests when appropriate. A p-value less than 0.05 will be considered statistically significant.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Children aged 6-12 years at enrollment.
  • Spherical equivalent refractive error between -0.75 and -6.00 diopters.
  • Astigmatism ≤1.50 diopters.
  • Best-corrected visual acuity of 0.1 logMAR or better.
  • Ability to comply with full-time spectacle wear.
  • Informed consent obtained from parent or legal guardian.

Exclusion criteria

  • Amblyopia or strabismus.
  • Keratoconus or other corneal pathology.
  • Previous myopia control treatment (e.g., atropine therapy, orthokeratology).
  • History of ocular surgery.
  • Systemic disease affecting vision.
  • Poor compliance with spectacle wear.

Treatment and study plan

Cylindrical Annular Refractive Element (C.A.R.E.) Spectacle Lenses

Device

C.A.R.E. spectacle lenses feature a central optical zone for distance correction surrounded by concentric annular cylindrical elements that modify peripheral retinal defocus to slow axial elongation in children with myopia. Participants were instructed to wear the lenses full-time during waking hours for 12 months. Follow-up assessments were conducted at baseline, 6 months, and 12 months, measuring axial length, refractive error, visual acuity, and safety.

Other names: C.A.R.E. lenses

Primary outcomes

  1. Change in Axial Length

    Time frame: Baseline to 12 months

    Axial length (AL) will be measured using non-contact optical biometry at baseline, 6 months, and 12 months. The primary outcome is the difference in axial length from baseline to 12 months to evaluate the effect of C.A.R.E. lenses on slowing ocular elongation in children with myopia.

Secondary outcomes

  1. Change in Spherical Equivalent Refractive Error (SER)

    Time frame: Baseline to 12 months

    SER measured under cycloplegia using an autorefractor at baseline, 6 months, and 12 months to assess myopia progression.

Sponsors and collaborators

Lead sponsor

Benha University

Other

Registry information

Official study title

Slowing Axial Elongation in Pediatric Myopia: One-Year Clinical Outcomes of Cylindrical Annular Refractive Elements (C.A.R.E.) Technology

Acronym: MyoCARE

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Mar 12, 2026
Registry last updated
Mar 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.